Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 10—October 2019
Dispatch

Tick-Borne Encephalitis in Auvergne-Rhône-Alpes Region, France, 2017–2018

Elisabeth Botelho-NeversComments to Author , Amandine Gagneux-Brunon, Aurelie Velay, Mathilde Guerbois-Galla, Gilda Grard, Claire Bretagne, Alexandra Mailles, Paul O. Verhoeven, Bruno Pozzetto, Sylvie Gonzalo, Samira Fafi-Kremer, Isabelle Leparc-Goffart, and Sylvie Pillet
Author affiliations: University Hospital of Saint-Etienne, Saint-Etienne, France (E. Botelho-Nevers, A. Gagneux-Brunon, P.O. Verhoeven, B. Pozzetto, S. Gonzalo, S. Pillet); Strasbourg University, Strasbourg, France (A. Velay, S. Fafi-Kremer); Aix-Marseille University, Marseille, France (M. Guerbois-Galla, G. Grard, I. Leparc-Goffart); Antoine Béclère Hospital, Clamart, France (C. Bretagne); French National Public Health Agency, Saint-Maurice, France (A. Mailles)

Main Article

Table 2

Results of serologic testing for arboviruses and Lyme disease for 3 patients with tick-borne encephalitis, Loire and Haute-Loire, Auvergne-Rhône-Alpes Region, France, 2017–2018*

Case no., sample
Days after clinical onset
TBEV

DENV

CHIKV

ZIKV

WNV

TOSV

Borrelia burgdorferi
IgM
IgG
IgM
IgG
IgM
IgG
IgM
IgG
IgM
IgG
IgM
IgG
IgM
IgG
1
CSF 16 4.3 3.22 1 1.12 <1 <1 <1 1 1 1.14 ND ND
Serum 19 6.6 2.94 1.16 1.24 <1 1.1 ND ND <1 1.24 <1 1 Neg Neg
Serum
48
7.1
10.6

1.11
1.10

1
1

ND
ND

ND
ND

ND
ND



2†
CSF
15
53.4
748.62

ND
ND

ND
ND

ND
ND

ND
ND

ND
ND

Neg
Neg
3
CSF 2 2.84 1.74 1.09 <1 <1 <1 <1 <1 <1 1 ND ND Pos‡
Serum ND ND ND ND ND ND ND ND ND ND ND ND ND Neg Pos
CSF 10 7.26 6.41 1.05 1.41 <1 1.02 <1 <1 <1 1.39 <1 <1 Pos
Serum‡ 10 2.34 3.02 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 Neg Pos
Serum 61 4.02 5.19 1.02 2.10 1.02 <1 <1 1 1.06 3.70 ND ND ND ND

*For cases 1 and 3, the results of ELISA serologic testing performed at the National Reference Centre for Arboviruses (Marseille, France) are expressed as the ratio between the optical density obtained with each viral antigen and the optical density with the control antigen. A ratio of <2.5 is considered a negative result; a ratio of 2.5–3.0 is considered an undetermined result; a ratio of >3 is considered a positive result. Lyme borreliosis serology was performed with Vidas immunoassays (bioMérieux, https://www.biomerieux.com). Serum specimens reacting for Borrelia burgdorferi IgG were also tested with Western blot; reactivity was observed for all cases with the lipoprotein VIse (a variable surface antigen of B. burgdorferi), and 17-, 39-, and 83-KDa proteins. Serologic testing for case-patient 2 was performed at the Laboratory of Virology at Strasbourg (Strasbourg, France) by using commercial assays (SERION ELISA classic TBE Virus IgG/IgM; https://www.virion-serion.de/en) and were interpreted according to the manufacturer’s instructions; results are expressed as U/mL, and positive cutoff values were 15 U/mL for TBEV IgM and 150 U/mL for TBEV IgG. Lyme borreliosis serology was performed with Enzygnost immunoassays (Siemens, https://www.siemens-healthineers.com). Boldface indicates positive results. CHIKV, chikungunya virus; CSF, cerebrospinal fluid; DENV, dengue virus; ND, not done; TBEV, tick-borne encephalitis virus; TOSV, Toscana virus; WNV, West Nile virus; ZIKV, Zika virus.
†Serologic testing could not be performed on serum sample.
‡The Reiber index showed a CSF/serum IgG ratio of 1.03 (i.e., an equivocal result of <2).

Main Article

Page created: September 17, 2019
Page updated: September 17, 2019
Page reviewed: September 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external